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ABSTRACT
The 5-hydroxytrptamine receptor 4 (5-HT4 receptor) is heavily expressed on
colonic epithelial cells and has been targeted as a therapeutic for functional bowel
symptoms and pain; however, adverse cardiac events related to 5-HT4 agonist treatment
limited their therapeutic use. Previous studies in the Mawe laboratory have demonstrated
that intraluminal application of a 5-HT4 agonist exerts protective epithelial actions in
animal models of colitis, and accelerates recovery from colitis. The aim of this study was
to test the effects of a luminally restricted 5-HT4 agonist in a mouse model of
experimental colitis.
The luminally restricted 5-HT4 agonist (Takeda Pharmaceuticals; 10 mg/kg) was
administered to mice during active dextran sodium sulfate (DSS) induced colitis. Colitis
activity was evaluated using disease activity index, a fecal lipocalin-2 assay, and
histological damage scoring. Epithelial proliferation and colonic motility were also
measured as readouts of the potential protective actions and colonic function,
respectively.
Oral gavage and intracolonic delivery of this luminally restricted 5-HT4 agonist
had no detectable effect on recovery from colitis or colonic motility as compared to
vehicle. Additionally, in positive control experiments, we failed to see an effect of the
5-HT4 agonist, tegaserod, on colitis severity or colonic motility in any of the measures
tested.
In conclusion, it is unclear if the luminally restricted 5-HT4 agonist has any effect
on recovery from DSS colitis. Given inconsistencies with the model and lack of an effect
of tegaserod, additional studies will be required, possibly involving different doses and
time points, to fully assess the actions of this luminally restricted compound in colitis
recovery.
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CHAPTER 1: LITERATURE REVIEW
I. Structure and Organization of the Gastrointestinal Tract1
A.   Organization of the Gastrointestinal Tract
The gastrointestinal (GI) tract is a long tube that begins in the mouth and ends at
the anus. Each part of the GI tract is specialized to serve the overall function of the organ
system, which is to breakdown ingested food into absorbable molecules, and to absorb
those molecules for use as nutrients. While the GI tract has specialized parts, the basic
structure of the gut wall is maintained throughout the length of the organ system. The
four tissue layers of the gut are the mucosa, submucosa, muscularis externa and serosa.
Additionally, the gut contains its own nervous system, the enteric nervous system, that is
organized as several sets of ganglionated plexi, and that serve to coordinate the
movements and functions of the gut. The myenteric (Auerbach’s) plexus is located within
the muscularis externa and serves to control motor patterns, and the submucosal
(Meissner’s) plexus is located within the submucosa and helps to coordinate secretion
and vasodilation. The enteric nervous system is highly specialized and autonomous,
receiving only moderate autonomic input from the central nervous system via the vagus
nerve, sacral spinal roots S2-4, and prevertebral ganglia (celiac, superior and inferior
mesenteric ganglia) within the abdominal cavity.
Starting from the mouth, food first enters the oral cavity and is mechanically
broken down by mastication, and enzymatically by salivary amylase. From here, food is
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  Information within this section is textbook material. See Silverthorn DJ, BR; Ober, WC; Garrison, CW;
Silverthorn, AC (2013) Human Physiology: and Integrated Approach. Pearson.
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swallowed and descends the esophagus via peristalsis, passes through the lower
esophageal sphincter and enters the stomach. The stomach serves to temporarily store
food, further digest food using acids, lipases and peptidases, and control the rate at which
food enters the duodenum. Specialized parietal cells are responsible for maintaining the
acidic environment of the stomach by secreting hydrochloric acid. The acidic
environment of the stomach is important not only for helping to break down food
particles, but also to kill any potential bacterial hazards. This acid, along with the other
enzymes and mechanical movement, begin the process of digestion, primarily breaking
down large food particles to create a soupy substance known as chyme. Chyme exits the
stomach via the powerful pyloric sphincter and enters the duodenum.
The duodenum is the first part of the small intestine and secretes alkaline mucus
from Brunner’s glands to neutralize the acidic pH of the semi-solid chyme exiting the
stomach. Two accessory GI organs, the pancreas and the gallbladder, secrete their
contents into the duodenum at the ampulla of Vater. The entrance of these substances is
controlled by the small circular muscle that surrounds the ampulla, called the sphincter of
Oddi. The pancreas synthesizes many digestive enzymes, and the gallbladder stores and
concentrates bile which contains enzymes to help break down fats. The distal two regions
of the small intestine are the jejunum and ileum, respectively. Their border is ill-defined,
but differences can be noted in the thickness of the mucosa. The jejunum has a thicker,
more folded mucosa, while the ileum has a thinner mucosa and the presence of Peyer’s
patches, seen as mounds under the epithelium. Peyer’s patches are nodes of lymphatic
tissue contained within the submucosal layer of the gut, and play an important role in
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maintaining gut homeostasis. The main function of the small intestine is to further break
down food particles into nutrients and then readily absorb those nutrients into the
bloodstream. The mucosa of the small intestine has specialized folds to increase surface
area, including mucosal folds (plica circulares in the jejunum), villi (finger-like
projections of mucosa), and microvilli (on the luminal side of individual epithelial cells).
These specialized folds result in a 20-30 fold increase in surface area, resulting in more
efficient nutrient absorption. Additionally, peristalsis and segmentation help to mix and
mechanically break down food particles. Peristalsis is a coordinated motor pattern that
helps push contents forward through the gut. Segmentation occurs to help mix intestinal
contents with the digestive enzymes, and to ensure that all chyme contacts the absorptive
mucosa. The small intestine empties into the cecum, which is located at the base of the
ascending colon. The ileocecal valve prevents retrograde movement of intestinal contents
back into the small intestine.
The large intestine is the final portion of the gastrointestinal system and serves to
manage waste excretion and fluid balance. The large intestine consists of the cecum,
colon and rectum. In humans, the large intestine can be divided in to four segments – the
ascending colon, the transverse colon, the descending colon, and the sigmoid colon,
which is directly followed by the rectum. In rodents, the colon has simply a distal and
proximal part. The large intestine is noted for the prominent bands of longitudinal muscle
running along the length of the colon called teniae coli. These bands of muscle are shorter
than the length of the colon, which causes the colon to bunch. This bunching creates
bulges called haustra. Additionally, the colon is histologically different than the small
3
	
  

intestine, containing no villi and instead having crypts of Lieberkühn, also called colonic
glands. These glands contain predominately enteroctyes, but also contain more mucus
secreting goblet cells than the small intestine. Specialized Enteroendocrine cells are
generally located in the bottom third of the colonic glands. Finally, the rectum is the last
portion of the GI tract and connects to the anus. It stores intestinal contents until time for
defecation.

B.   Tissues of the Gastrointestinal System
The wall of the GI tract can be divided into three layers: the mucosa, the
submusoca and the muscularis propria. Starting most centrally, the epithelium of the gut
is in contact with the contents of the lumen. Deep to the epithelium lies the lamina
propria. Deep to the lamina propria lies the muscularis mucosa and then the submucosa.
The submucosal ganglia are located within the submucosal space. Outside of the
submucosa sits the muscularis propria which contains a layer of longitudinal and a layer
of circular muscle, with the myenteric nerve plexus sitting in between.

1.   Mucosa
The mucosal layer of the GI tract is comprised of three sublayers – the epithelium,
lamina propria and muscularis mucosa. The epithelial layer is a heterogeneous mix of cell
types, including enterocytes, Paneth cells, enteroendocrine cells, and goblet cells, with
the latter two only present in the stomach and intestines. These cells have specialized
functions and help to both protect the tissue, and maintain barrier function. The epithelial
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layer in the oral cavity, pharynx, and esophagus is made of non-keratinized, stratified
squamous epithelium, whereas the stomach and intestines contain simple columnar
epithelium. Additionally, the epithelium of the stomach and intestines is organized into
tubular glands, or folds. These folds help to not only increase surface area for nutrient
absorption in the small intestine (plicae circulares), but also allow for expansion of the
stomach to accommodate food intake (rugae), and restrict the movement of intestinal
contents within the colon. The lamina propria is a layer of loose connective tissue that
provides vascularization to the epithelium and houses mucosal glands and gut associated
lymphoid tissues, including B and T lymphocytes and dendritic cells. Together, the
epithelium and the immune cells in the lamina propria work to maintain barrier function
and homeostasis within the gut. Lastly, the muscularis mucosa is a thin muscular layer
beneath the lamina propria that modulates the surface area of the lumen. Contraction
causes the rugae of the stomach and plicae circulares of the small intestine to decrease the
available surface area, whereas relaxation of the muscularis mucosa causes those
structures to expand, increasing the available surface area.

2.   Submucosa
The submucosa is a rich connective tissue layer that houses the submucosal
plexus of the enteric nervous system. In some areas of the gut, such as the duodenum, this
layer contains glands that secrete contents into the lumen to aid in the digestive process.
This layer is also rich in blood vessels and lymphatics. The submucosal plexus is
responsible for coordinating secretory reflexes, as well as vasodilatory reflexes.
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3.   Muscularis Externa
The muscularis externa is comprised of two muscular layers and one ganglionated
plexus. The myenteric plexus is sandwiched between a layer of circular muscle and a
layer of longitudinal muscle. These two layers of muscle contract and relax in a
coordinated fashion to produce motor patterns within the gut, including segmentation and
peristalsis. Segmentation occurs when adjacent sections of gut contract and relax in a
coordinated manner to allow for mixing of luminal contents. Peristalsis causes the
forward movement of luminal contents by an upstream contraction and a downstream
relaxation. These motor patterns are coordinated primarily by the myenteric plexus, with
little extrinsic input from the central nervous system.

4.   Serosa
The serosa, or adventitia layer, is a sheet like membrane covering the outside of the
gut, and is made of a single layer of mesothelial cells. The parts of the GI tract that are
intraperitoneal are covered with serosa, while the retroperitoneal parts, the esophagus,
and the oral cavity are covered in adventitia. The serosa and the adventitia layer both
serve the role of providing an external layer of tissue to these organs. The serosa is
continuous with the visceral peritoneum lining the abdominal cavity. It contains blood
vessels, lymphatics and nerves, and, within the intraperitoneal space, is connected to the
mesentery.
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II. Serotonin
	
  
A.   History
The substance now known as serotonin was first isolated from rabbit gastric
mucosa by the Italian pharmacologist Vittorio Erspamer in 1937 (Erspamer V, 1937). He
named this bioactive amine, enteramine, as he identified it in the GI tracts of almost
every vertebrate he studied. Later, a compound with vasoconstrictive properties was
identified in bovine serum by researchers at the Cleveland Clinic. Maurice Rapport, Arda
Green and Irvine Page called this compound serotonin due to its effect increasing
vascular tone (Rapport et al., 1948). In time, these two molecules were discovered to be
the same, 5-hydroxytryptamine, and the name serotonin was adopted for general use.

B.   Gastrointestinal Mucosal Serotonin
Serotonin (5-hydroxytryptamine, 5-HT) is an important signaling molecule for
many physiological systems, and it plays a particularly crucial role within the GI tract
(Mawe and Hoffman, 2013). The mucosa of the GI tract contains the body’s largest store
of 5-HT. It is synthesized from tryptophan, using the enzyme tryptophan hydroxylase-1
(TPH-1), by enterochromaffin (EC) cells within the gut epithelium. Once synthesized it is
stored in intracellular granules along the basal side of EC cells until released into the
lamina propria. Release can be stimulated by intraluminal changes in acidity, pressure, or
increased nutrient concentration. Once within the lamina propria, 5-HT interacts with a
variety of cell types, including enteric neurons, extrinsic neuron projections, epithelial
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cells and immune cells. The precise action of 5-HT depends on the type of receptor that is
expressed.
To terminate 5-HT signaling, molecules are removed from the extracellular space
via the serotonin-selective reuptake transporter (SERT) protein. SERT is expressed on
serotonergic enteric neurons and virtually all intestinal epithelial cells. Once 5-HT has
been transported into cells by SERT, it is either degraded by intracellular degradative
enzymes, such as monoamine oxidases, or is repackaged into vesicles. Any 5-HT not
transported out of the interstitial space will enter the blood stream via the dense capillary
bed in the lamina propria, and be taken up by blood platelets, which also express SERT.
Altered serotonin signaling within the GI tract is implicated in human
inflammatory bowel diseases (IBD) such as Crohn’s Disease and Ulcerative Colitis.
Changes in GI serotonin content, EC cell density and SERT expression have been
reported in both human disease and animal models of colitis (Coates et al., 2017). It is
also known that serotonin can modify GI motility and that activation of epithelial
serotonin receptors has protective epithelial actions and promotes recovery from colitis
(Hoffman et al., 2012, Spohn et al., 2016). It should also be noted that serotonin exerts
pro-inflammatory actions in the GI tract through activation of 5-HT7 receptors on
dendritic cells (Spohn and Mawe, 2017).

C.   5-HT4 Receptor
There are seven classes of 5-HT receptors (5-HT1 – 5-HT7), with 13 distinct
subtypes, 7 of which are expressed in the GI tracts of humans (5-HT1A, 5-HT2A, 5-HT2B,
8
	
  

5-HT3, 5-HT4, and 5-HT7)(Mawe and Hoffman, 2013). They have been identified on a
variety of cell types within the gut, including enterocytes, goblet cells, EC cells, neurons,
immune cells, smooth muscle cells and interstitial cells of Cajal. One receptor subtype,
the 5-HT4 receptor, plays an important role in gastrointestinal homeostasis and motility.
The 5-HT4 receptor is a G-protein coupled receptor, that is Gs coupled and activates the
adenylate cyclase/cyclic adenosinemonophosphate (cAMP)/protein kinase A pathway.
Thus, it plays a role in many different cellular functions including, but not limited to,
prosecretory actions and facilitation of neurotransmitter release (Tonini et al., 1989, Pan
and Galligan, 1994, Hoffman et al., 2012)
The 5-HT4 receptor is expressed on enteric nerve terminals, where it helps to
mediate neurotransmitter release through presynaptic facilitation (Pan and Galligan,
1994). It has also been demonstrated that 5-HT4 receptor stimulation promotes enteric
neuronal survival and neurogenesis (Liu et al., 2009). This receptor is also heavily
expressed on colonic epithelial cells, where it helps to mediate 5-HT release from
enterochromaffin cells, stimulates chloride secretion from enterocytes, and promotes
goblet cell degranulation (Hoffman et al., 2012). Furthermore, activation of epithelial 5HT4 receptors has been shown to stimulate propulsive motility, decrease visceral
hypersensitivity, promote epithelial proliferation and promote the integrity of the
epithelial barrier (Spohn et al., 2016).
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D.   Mucosal 5-HT4 Receptor Actions
There is strong evidence for mucosal 5-HT4 receptors mediating the prokinetic,
anti-nociceptive and anti-inflammatory actions within the gastrointestinal tract. The 5HT4 receptor is specifically expressed by a multitude of cells types in the epithelium of
the GI tract, including 5-HT containing enterochromaffin (EC) cells, mucin-2 containing
goblet cells and enterocytes in human and mouse tissues (Hoffman et al., 2012, Spohn et
al., 2016)

1.   Prokinetic Actions
5-HT4 agonists have potent prokinetic actions that have been identified through
multiple mechanisms and at multiple sites of action. Our lab previously reported that
activation of EC cells with a 5-HT4 agonist results in an increased release of 5-HT and
increases in goblet cell cavitation and mucus release (Hoffman et al., 2012). It has also
been shown that stimulation of the cAMP/PKA pathway in human colonic cell lines
results in mucus secretion (Bradbury, 2000). This implies that mucus release could result
from direct activation of mucosal 5-HT4 receptors. Lastly, it is known that 5-HT increases
chloride secretion in GI epithelium and that application of 5-HT4 agonists to mouse
colonic tissue increases the ISC current (Budhoo et al., 1996, Ning et al., 2004, Hoffman
et al., 2012). Together, these three actions of 5-HT4R activation may contribute to
increasing propulsive motility of the GI tract in the following ways: (1) Increases in 5-HT
release can directly activate peristaltic reflex circuitry; (2) Increases in mucus secretion
may help decrease intraluminal friction, easing the passage of luminal contents; and (3)
10
	
  

Increases in chloride secretion result in increased water content in the lumen, softening
stool and allowing for ease of passage. Furthermore, 5-HT4 agonists have been shown to
directly increase colonic motility in healthy and inflamed colons of guinea pig and mice
by directly activating peristaltic reflex circuitry (Grider et al., 1998, Jin et al., 1999,
Spohn et al., 2016). Together, these results indicate a potent prokinetic effect of 5-HT4
receptor activation.

2.   Anti-nociceptive Actions
Anti-nociceptive effects of 5-HT4 agonists have been observed in rat models of
hypersensitivity and in clinical trials in humans. The 5-HT4 agonist tegaserod alleviates
abdominal pain and discomfort in rats, as seen by a decrease in colonic hypersensitivity
(Greenwood-Van Meerveld et al., 2006, Hoffman et al., 2012). Greenwood-Van
Meerveld and colleagues demonstrated that rats with both acute and chronic
hypersensitivity showed a decreased visceral motor response to colorectal distention after
oral or intracolonic treatment with tegaserod. The response to intracolonically delivered
tegaserod was blocked by pretreatment with the 5-HT4 selective antagonist GR113808.
Multiple clinical trials have reported a significant decrease in perceived abdominal pain,
a decrease in straining and an improvement in stool consistency for IBS patients treated
with tegaserod as compared to control patients (Novick et al., 2002, Chey et al., 2008).
The exact mechanism by which 5-HT4 activation alters visceral hypersensitivity is
unknown.
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3.   Protective Epithelial Actions
Our lab has demonstrated the protective actions of mucosal 5-HT4 receptors in a
multitude of animal models and assays. Intracolonic tegaserod treatment decreased
clinical and histological damage scores in both the 2,4,6-trinitrobenzine sulfonic acid
(TNBS)(mouse and guinea pig) and dextran sodium sulfate (DSS)(mouse) models of
colitis (Spohn et al., 2016). Intraperitoneal administration of a 5-HT4 agonist did not
provide a protective effect, and the protective and restorative effects of intracolonic
treatment were blocked by antagonist treatment (Spohn et al., 2016). In addition, these
effects were not present in 5-HT4 deficient mice. These results suggest that activation of
the 5HT4 receptor is sufficient to induce a protective response in experimental colitis.
Furthermore, tegaserod treatment in mice with DSS colitis improved epithelial barrier
function as seen by a decrease in bacterial translocation to the spleen or liver (Spohn et
al., 2016). Lastly, treatment of Caco-2 cells, a human epithelial colorectal
adenocarcinoma cell line, with tegaserod resulted in increased resistance to oxidative
stress, and an increased rate of cell migration following an in vitro scratch assay (Spohn
et al., 2016). These results were blocked by antagonist treatment. Together, these actions
suggest a potent protective effect of epithelial 5-HT4 receptor activation in vivo and in
vitro.

E.   Epithelial 5-HT4 receptors as a therapeutic target
The 5-HT4 receptor has been identified as a potent therapeutic target for
constipation relief in irritable bowel syndrome (IBS) and chronic constipation, as well as
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pain relief in IBS; however, off-target cardiac effects have limited their use in clinical
populations (Novick et al., 2002, Chey et al., 2008, Tack et al., 2012).
Agonists of the 5-HT4R, including cisapride and tegaserod, have had remarkable
clinical success for patients with constipation and constipation predominant IBD;
however, their use in patient populations was suspended or restricted after reports of
adverse cardiovascular events (McCallum et al., 1988, Evans et al., 2007, Tack et al.,
2012).
Tegaserod was removed from the market in 2007 by recommendation from the
FDA based on evidence from pooled clinical trial data suggesting a risk of ischemic
cardiovascular events (Wooltorton, 2004). However, it is unknown how tegaserod led to
these adverse events. Tegaserod has a low affinity for the 5-HT1B receptor located on
blood vessels, but causes vasodilation, and thus would not lead to ischemia. A large,
matched-cohort study in 2010 detected no increase in ischemic cardiovascular events in
tegaserod users (Loughlin et al., 2010).
Cisapride is a benzamide, with moderate affinity and poor selectivity for the 5HT4 receptor (Nagakura et al., 1999). It also blocks 5-HT2, 5-HT3, and the human ethera-go-go-related gene (hERG)- encoded K+ channel (Nagakura et al., 1999, Potet et al.,
2001). The hERG channel is present on cardiac smooth muscle cells, and it is thought
that blockage of this channel led to a lengthening of the QT interval, causing the adverse
cardiac events, particularly in individuals with long QT syndrome (Drolet et al., 1998).
While 5-HT4 agonists other than cisapride have shown to have low to no-binding
capacity for the hERG-K+ channel, or other K+ or Na2+ channels, there is still a stigma
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and fear associated with serotonin receptor agonists as a therapeutic target (Tack et al.,
2012). Since these side effects were a result of systemic availability, a therapeutic in
which the active compound is not absorbed systemically could yield the same efficacy
without the potential for dangerous off-target effects.

II. Inflammatory Bowel Disease
	
  
Inflammatory Bowel Disease (IBD) is a condition of chronic or relapsing/remitting
inflammation of the gastrointestinal tract. IBD is an umbrella term that includes Crohn’s
disease (CD) and Ulcerative Colitis (UC). This disease typically manifests between the
second and third decade of life, and predominately affects women over men. According
to the CDC, in 2015 the prevalence of IBD diagnosis was 1.3% (3.1 million) of U.S.
adults, which increased from 0.9% (1.8 million) in 1999. This study showed a higher
prevalence in adults over the age of 45, Hispanics, non-Hispanic whites, and adults with a
less than high school education (Dahlhamer, 2016). However, other studies have shown
increased prevalence at higher socioeconomic levels (Krishnan and Korzenik, 2002).
There is extensive physical and financial burden on those suffering from IBD.
According to a 2008 study, the average annual cost for those suffering from IBD is
between $5000 and $10,000 (Kappelman et al., 2008). Additionally, there is a higher
hospitalization rate for individuals with IBD, and most patients will require surgery at
least once in their lifetime (Bewtra et al., 2007). There is no current cure of IBD, only
life-long palliative treatments.
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The etiology of IBD is unknown. It is thought that a combination of altered gut
microbiota and aberrant mucosal immune responses due to diet and environmental factors
in genetically susceptible individuals leads to development of IBD (Matsuoka et al.,
2018). There have been 163 susceptibility loci identified for IBD, including
approximately 300 potential genes (Loddo and Romano, 2015). The first IBD associated
gene discovered was for nucleotide-binding oligomerization domain containing 2
(NOD2), which codes for an intracellular pattern recognition receptor. Bacterial binding
to this protein induces autophagy in dendritic cells, and mutations in this protein are
associated with CD (Cooney et al., 2010). There is a prominent familial component to
IBD, with relatives of CD or UC having an 8- to 10-fold greater risk for developing IBD,
and there is concordance between twins (Cho and Brant, 2011). The immunopathogenesis
of IBD is still being elucidated, and is vastly complex. Simply, it appears that CD is
primarily TH1 mediated and UC is primarily TH2 mediated; however, there is significant
overlap in their immunologic profiles (Wallace et al., 2014). CD and UC share
overlapping etiologies, but they differ anatomically and histologically, as described
below.

A.   Crohn’s Disease
Crohn’s disease (CD) can affect any part of the gastrointestinal tract, but
commonly affects the distal small intestine, and the proximal colon. It is characterized
by discontinuously affected areas of inflammation, transmural immune cell
infiltration and fistulas. The major symptoms of Crohn’s include diarrhea, abdominal
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pain, weight loss, fever, and less frequently bloody or mucus covered stool.
Genetically, CD is primarily associated with genes for lymphocyte chemotaxis and
trafficking genes (Franke et al., 2010).

B.   Ulcerative Colitis
Ulcerative colitis (UC) most prominently affects the colon, primarily the distal
side, and has a continuous area of inflammation. Histologically, the inflammation
only affects the mucosal layer, leaving the deeper layers of the gut unaffected, and
often forms erosions. The major symptoms of UC include recurrent bloody diarrhea,
abdominal pain and frequent bowel movements. Genetically, UC is associated with
genes that regulate barrier function, including proteins involved in epithelial tight
junction integrity (Anderson et al., 2011). UC is also associated with an increased risk
in colon cancer.

C.   Current Therapies
The predominant current therapies for IBD include anti-inflammatory,
immunosuppressive, and biologic therapies (Neurath, 2017). Anti-inflammatory drugs
include 5-aminosalicylates (5-ASAs) and corticosteroids. While both are effective at
inducing remission, only 5-ASAs help to maintain remission. Immunosuppressive
therapies, including azathioprine, methotrexate and circlosporin-A, have efficacy
inducing and maintaining remission of both CD and UC. Lastly, biologic therapies,
including monoclonal antibodies that target tumor necrosis factor (TNF)-alpha
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(infliximab, adalimumab, golimumab and certolizumab pegol), have been used to
induce and maintain remission in UC and CD. Studies have shown that combined
immunosuppressive and biologic therapies are more effective at inducing and
maintaining remission than either therapy alone for both UC and CD (Colombel et al.,
2010, Panaccione et al., 2014).
Given the complex etiology and the varied cytokine profiles of IBD patients, it is
challenging to find the appropriate therapeutic for a given individual. Approximately
30-50% of patients do not respond to anti-TNF agents, and there is a significant risk
of relapse after discontinuation of anti-TNF therapy (40% in CD and 28% in UC)
(Olesen et al., 2016, Neurath, 2017). To fill this void, many new therapeutic targets
are currently being studied, including integrin blockers and modulators of T-cell
trafficking (alpha-4beta-7, beta-7, MAdCAM1, and S1P receptor agonists), matrix
metalloprotease inhibitors to mediate fibrosis and tissue remodeling (MMP 9
inhibitors CHST15 siRNAs), blockers of transcription factors and modulators of
barrier function and anti-inflammatory pathways (Neurath, 2017).
The therapies described above are useful, but up to 40% of patients still
experience other functional bowel symptoms, even when the disease is in remission
(Coates et al., 2013, Vivinus-Nebot et al., 2014). These functional bowel symptoms
include abdominal pain and changes in bowel habits that, while not inherently
dangerous, severely affect the patient’s quality of life. Traditional therapies are
targeted at dampening the immunological component of IBD; however, there is a
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clear need for novel therapies targeting these functional bowel symptoms experienced
by most patients.
	
  
III. Animal Models of Colitis
	
  
There is no perfect animal model that recapitulates all features of human
inflammatory bowel disease; however, there are a few different models that have key
features of IBD. These models include the chemically induced models: dextran sodium
sulfate, TNBS, and oxazolone; and spontaneous colitis in interleukin(IL)-10 deficient
mice (Kiesler et al., 2015, Wirtz et al., 2017). These methods all reproduce histological,
pathological and immunologic hallmarks of inflammatory bowel diseases, the details of
which are described below:

A.   Dextran Sodium Sulfate
DSS colitis is induced by oral administration of the sulfated polysaccharide
dextran sodium sulfate. This experimental colitis recapitulates the clinical and
inflammatory features of ulcerative colitis (Okayasu et al., 1990). The exact
mechanism is not entirely understood, but it is thought that the molecule is taken up
into epithelial cells, altering tight junction proteins, and leading to compromised
barrier function. The increased epithelial permeability allows luminal bacteria and
their by-products to interact with mucosal and submucosal immune cells, resulting in
rapid and intense inflammation. It has been hypothesized that DSS creates nanolipocomplexes with fatty acids that fuse to the membranes of epithelial cells, and
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penetrate the cell membrane, depositing DSS molecules intracellularly, thus affecting
barrier permeability (Laroui et al., 2012). These changes in barrier function are likely
due to alteration in tight junction protein expression. It has been shown that DSS can
alter ribosome interactions (Miyazawa et al., 1967). Furthermore, it is known that the
cytokines IL-1b and IL-18 play crucial roles in the development of DSS colitis, and
that the NLRP3 inflammasome is necessary for DSS colitis to develop, indicating a
role for the innate immune system (Bauer, 2010). Additionally, immune deficient
mice are susceptible to DSS, showing that the adaptive immune system is not
required for this immune response (Dieleman et al., 1994); however, TH1 and TH2
cytokines are present in experimental models of chronic colitis (Dieleman et al.,
1998). DSS induced colitis is an acceptable model to study the features of ulcerative
colitis, particularly impaired barrier function.

B.   Trinitrobenzine Sulfonic Acid
TNBS is a haptenizing agent that is administered intracolonically with ethanol.
The ethanol allows the TNBS to access the epithelial cells and penetrate the gut wall.
TNBS colitis predominately recapitulates the features of CD, including infiltration of
CD4+ T-cells and neutrophils, transmural inflammation, spontaneous resolution of
inflammation, fibrosis of the mucosal tissue, severe diarrhea, weight loss and rectal
prolapse (Neurath et al., 1995, Kiesler et al., 2015). Additionally, TNBS colitis and
CD are both characterized by a TH1 and TH17 CD4+ T-cell dominant response,
involving cytokines IFN-g and IL-17 (Strober and Fuss, 2011).
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This experimental colitis model has been particularly useful in studying the role
of the adaptive immune system and T cell responses in inflammatory bowel disease.
However, the role of the innate immune system should not be understated, as immune
deficient mice are still susceptible to TNBS administration (Fiorucci et al., 2002).
This is because IL-12 production by innate cells is necessary to drive the T-cell
response.

C.   Other Models of IBD: IL-10 knockout and Oxazolone colitis
Interleukin-10 knockout mice spontaneously develop colitis between 4 and 8
weeks of age, with inflammation featuring infiltration of lymphocytes, macrophages
and neutrophils into the intestinal mucosa (Kuhn et al., 1993). This model has been
useful for assessing immunoregulation and macrophage involvement in gut
homeostasis. The inflammatory response in IL-10-/- mice is initially driven by TH1
cells and related cytokines; however, this response slowly subsides and a TH2, IL-4
and IL-13 driven response becomes the dominant profile (Spencer et al., 2002). This
phenomenon gives insight into the dynamic changes in immunoregulation occurring
in gut inflammation that may parallel human IBD.
Oxazolone is another haptenizing agent that, when applied intracolonically
induces colonic inflammation. The features of oxazolone colitis align with features of
UC both morphologically and immunopathologically. It causes superficial
inflammation of the mucosa within the distal colon, including infiltration of
lymphocytes and neutrophils, and erosions (Boirivant et al., 1998). It is characterized
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by a TH2 cytokine profile, including IL-13 secretion from CD4+ natural killer T cells
in the lamina propria (Heller et al., 2002). IL-13 is known to cause and increase
epithelial cell apoptosis, an increase in the pore-forming tight junction protein
claudin-2, a decrease in the tight junction protein tricellulin and ultimately decreased
barrier function (Heller et al., 2005, Krug et al., 2017). This model is useful for
studying the immunopathogenesis of UC.

IV. Specific Aims
	
  
Serotonin is a very important signaling molecule within the gastrointestinal (GI) tract.
One receptor subtype, the 5-HT4 receptor, has been identified as a potent therapeutic
target for functional bowel disease and pain. Agonists of the 5-HT4 receptor, including
cisapride and tegaserod, have had remarkable clinical success as prokinetic agents;
however, adverse side effects due to systemic availability led to their removal from the
market. Our lab has recently discovered that 5-HT4 receptors are highly expressed in the
colonic epithelium, and that activation of these receptors promotes motility and induces
protective epithelial actions (Hoffman et al., 2012, Spohn et al., 2016). We hypothesize
that the administration of luminally restricted 5-HT4 agonists will accelerate recovery
from established colitis by inducing protective epithelial actions and restoring normal
motility patterns.
Aim 1: Evaluate the effect of luminally restricted 5-HT4 agonists on disease severity
in DSS colitis. Hypothesis: Administration of luminally restricted 5HT4 agonists by
enema will exert protective epithelial actions in the murine model of DSS induced colitis.
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A recovery paradigm will be used to test this hypothesis. The recovery paradigm will test
whether 5-HT4 agonist treatment, initiated after DSS colitis is established, accelerates
recovery from colitis. Outcome measures will include daily recordings of disease activity
index, fecal lipocalin-2 levels, analysis of epithelial proliferation, and histological
damage scores.
Aim 2: Evaluate the effect of luminally restricted 5-HT4 agonists on colonic motility
in DSS colitis. Hypothesis: Application of a luminally restricted 5-HT4 agonist will
increase colonic motility in vivo. This hypothesis will be tested using in vivo techniques
to elucidate functional outcomes of the luminally restricted agonist. Two assays will be
used to assess gastrointestinal function in DSS mice treated with the non-absorbable 5HT4 agonist: colonic motility and fecal output and consistency. These assays will be
performed throughout the DSS recovery paradigm.
The proposed studies are designed to elucidate the effects of luminally restricted
5-HT4 agonists on development of and recovery from colitis. We will use well validated
in vivo assays to determine the protective epithelial actions of this compound on the
gastrointestinal tract. These studies will examine the therapeutic potential of luminally
restricted 5-HT4 agonists for the treatment of IBD.
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CHAPTER II: PROTECTIVE ACTIONS OF LUMINALLY RESTRICTED 5-HT4
RECEPTOR AGONISTS IN DEXTRAN SODIUM SULFATE INDUCED
COLITIS
	
  
I. Abstract
Background: The 5-hydroxytrptamine receptor 4 (5-HT4 receptor) is heavily expressed
on colonic epithelial cells and has been targeted as a therapeutic for functional bowel
symptoms and pain; however, adverse cardiac events related to 5-HT4 agonist treatment
limited their therapeutic use. Previous studies in the Mawe laboratory have demonstrated
that intraluminal application of a 5-HT4 agonist exerts protective epithelial actions in
animal models of colitis, and accelerates recovery from colitis. The aim of this study was
to test the effects of a luminally restricted 5-HT4 agonist in a mouse model of
experimental colitis.
Methods: The luminally restricted 5-HT4 agonist SYR313832Z (Takeda
Pharmaceuticals; 10 mg/kg) was administered to mice during active DSS colitis. Colitis
activity was evaluated using disease activity index, a fecal lipocalin-2 assay, and
histological damage scoring. Epithelial proliferation and colonic motility were also
measured as readouts of the potential protective actions and colonic function,
respectively.
Results: Oral gavage and intracolonic delivery of SYR313832Z had no detectable effect
on recovery from colitis or colonic motility as compared to vehicle. Additionally, in
positive control experiments, we failed to see an effect of the 5-HT4R agonist, tegaserod,
on colitis severity or colonic motility in any of the measures tested.
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Conclusions: In conclusion, it is unclear if the luminally restricted 5-HT4 agonist
SYR313832Z has any effect on recovery from DSS colitis. Given inconsistencies with
the model and lack of an effect of tegaserod, additional studies will be required, possibly
involving different doses and time points, to fully assess the actions of SYR313832Z in
colitis recovery.

II. Introduction
Serotonin (5-hydroxytryptamine, 5-HT) is an important signaling molecule for
many physiological systems, and it plays a particularly crucial role within the
gastrointestinal (GI) tract. Within the GI tract, 5-HT acts as a neurotransmitter and
paracrine signaling molecule to stimulate motility, secretion, vasodilation and sensation
(Mawe and Hoffman, 2013). Altered serotonin signaling within the GI tract is implicated
in human inflammatory bowel diseases (IBD), such as Crohn’s Disease and Ulcerative
Colitis (Coates et al., 2017). Serotonin receptors have been the target of therapies for
functional gastrointestinal disorders and pain (Mawe and Hoffman, 2013). Unfortunately,
use of many of these therapies was suspended or restricted due to reports of adverse
cardiovascular events (De Maeyer et al., 2008).
Serotonin exerts its effects through activation of a family of G-protein coupled
receptors. One receptor, the 5-HT4 receptor, is a G-protein coupled receptor, that is Gs
coupled and activates the adenylate cyclase/cyclic adenosine monophosphate
(cAMP)/protein kinase A pathway. The 5-HT4 receptor, is expressed on enteric nerve
terminals, where it helps to mediate neurotransmitter release through presynaptic
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facilitation, and is amply expressed on colonic epithelial cells, where it mediates 5-HT
release from enterochromaffin cells, stimulates chloride secretion and goblet cell
degranulation (Pan and Galligan, 1994, Hoffman et al., 2012). Furthermore, activation of
mucosal 5-HT4 receptors has been shown to stimulate propulsive motility, decrease
visceral hypersensitivity, promote epithelial proliferation and promote the integrity of the
epithelial barrier (Spohn et al., 2016). In the outer layers of the intestines, 5-HT4 agonist
stimulation has been shown to promote neuronal proliferation and survival, and to
enhance growth of nerve fibers (Liu et al., 2009, Matsuyoshi et al., 2010, Belkind-Gerson
et al., 2015)
The 5-HT4 receptor, has been identified as a potent therapeutic target for
constipation relief in irritable bowel syndrome (IBS) and chronic constipation, as well as
pain relief in IBS (Novick et al., 2002, Chey et al., 2008, Tack et al., 2012). Studies from
our lab have shown that intracolonic administration of the 5-HT4 agonist, tegaserod,
improves colitis recovery over intraperitoneal administration in experimental models of
colitis (Spohn et al., 2016).
This study examined the hypothesis that a luminally restricted 5-HT4 agonist,
SYR313832Z, would exert protective epithelial actions and restore normal motility
patterns in murine dextran sodium sulfate induced colitis. We used a recovery paradigm
to investigate whether treatment of animals with active colitis would accelerate
recuperation. Outcome measures included recording disease activity index, examining
levels of fecal lipocalin-2, histological damage scoring, assessing epithelial proliferation,
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and measuring colonic motility. The measures tested in this study reveal no effect of the
luminally restricted agonist on colitis.

III. Methods
Animal Care and Use
All experimental protocols were approved by the Institutional Animal Care and
Use Committee of the University of Vermont. The animals used in this study were 8-10
week-old male CD-1 IGS mice (Charles River Laboratories, Saint-Constant, QC,
Canada). Animals were euthanized using isoflurane overdose followed by
exsanguination.

Experimental Paradigms
For these studies, the protective epithelial actions of the proprietary, luminally
restricted 5-HT4 agonist, SRY313832Z (832Z), were assessed in a paradigm modeling
recovery from induced colitis. 832Z was given to us by Takeda Pharmaceuticals for the
purposes of this study. Pharmacokinetics analyses by Takeda indicate that 832Z is not
detectable in the blood serum and it is heavily detected in colonic tissue up to 8 hours
after gavage administration.
Colitis was induced by addition of 3% or 4% DSS to the drinking water on days 0
through 5. On day 5, DSS water was replaced with tap water. Starting on day 5, mice
received daily administration (gavage or enema) of 832Z, tegaserod (positive control) or
vehicle for 10 consecutive days (see Table 1 for formulations). Mice were euthanized on
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day 15, and colon sections taken for histology and immunohistochemistry. To assess
levels of inflammation and colitis severity the following assays were used: disease
activity index score, histological damage score, and fecal lipocalin-2 levels. The
measures of colonic motility included fecal water content, fecal output and bead
expulsion. Any differences in the paradigm or drug administration protocol are noted in
the figure legends.

Vehicle
832Z
Tegaserod

Gavage
1% Tween80, 0.5% Methyl
Cellulose in tap water
10 mg/kg 832Z, 1%
Tween80, 0.5% Methyl
Cellulose in tap water
N/A

Enema
1% DMSO in 0.9% saline
1 or 10 mg/kg 832Z, 1%
DMSO in 0.9% saline
1 mg/kg tegaserod, 1%
DMSO in 0.9% saline

Table 1. Drug and vehicle formulations for 15 day recovery paradigm.

Disease Activity Index
Disease severity was assessed using a rubric score throughout the course of the
disease paradigm. This rubric includes the major pathological landmarks of colitis:
weight loss, stool consistency, and fecal blood. Each symptom is rated on a scale from 0
to 4; with a score of 4 being the most severe. The exact scoring criteria were adapted
from Cooper et. al. and is described in Table 2 (Cooper et al., 1993). This score was taken
every other day through out the experimental paradigm to track the progression of the
colitis. For the sake of this study, a score of 4-8 is considered moderate colits, whereas a
score greated than 8 is considered severe colitis.
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Score
0
1
2
3
4

Weight Loss
None
1-5%
5-10%
10-20%
>20%

Stool Consistency
Normal

Occult/gross bleeding
Normal

Loose stool

Hemoccult +

Diarrhea

Gross bleeding

	
  

Table 2. Details of disease activity index rubric.
	
  
Fecal Lipocalin-2 ELISA
Fecal pellets were collected over the course of the experiment and stored at -20
degrees Celsius. To prepare samples for the assay, fecal pellets were homogenized in
0.1% Tween20/PBS at 50 mg/mL, and then centrifuged for 5 minutes at 20,000 x g.
Supernatant was collected and diluted from 1:5 to 1:6000 depending on the time point of
the sample. Two dilutions were performed for each sample using the kit-recommended
diluent (1% BSA in PBS). Lipocalin-2 levels were determined using a solid phase
sandwich ELISA (Mouse Lipocalin-2/NGAL DuoSet ELISA kit, R&D Systems,
Minneapolis, MN), and levels compared between the treatment and control groups at all
time points. Dilutions that presented the most accurate duplicates and that fell within the
standard curve of the ELISA were used for analysis.

Histological Damage Score
Histological assessment of tissue damage is a classic method to determine the
extent of colitis. For this measure, small pieces of distal colon were fixed in 4% PFA and
0.1M sodium phosphate, paraffin embedded, sectioned, and stained using a hematoxylin
and eosin (H&E) stain. Sections were blindly scored according to a scoring rubric that is
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based on the classic histological features of human inflammatory bowel disease
(Villanacci et al., 2013, Spohn et al., 2016). Briefly, the rubric considers infiltration of
immune cells, cytoarchitecture, crypt architecture, epithelial integrity and ulcerations.
Scores were compared between treatment and control groups by an unpaired students ttest or one-way ANOVA, as appropriate.

Proliferation Assay
Epithelial cell proliferation was assessed using immunohistological staining for
the post-mitotic marker Ki-67, a technique that has been used previously to assess
epithelial proliferation in human and animal models of colitis (Joly et al., 2009, Hoffman
et al., 2012, Spohn et al., 2016). Paraffin-embedded sections of distal colon (same as used
for H&E staining), were co-stained for Ki-67 and the nuclear marker DAPI. Within each
crypt, the ratio of Ki-67+ cells:DAPI+ nuclei was counted. Three crypts were analyzed per
tissue section, and then averaged to give a percent of Ki-67+ cells per crypt. These
numbers were compared between groups using an unpaired students t-test.

Colonic Motility
The bead expulsion assay is an in vivo assay to assess colonic motility. This assay
has been used previously to assess in vivo colonic motility in DSS colitis (McClain et al.,
2014, Spohn et al., 2016). Briefly, the assay was performed by inserting a glass bead 2
cm into the rectum of a lightly anesthetized mouse and recording the latency from waking
of the animal to expulsion of the bead. Bead expulsion data were collected from each
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mouse before, during and after inflammation (approximately days 0, 5, and 15). This
technique allowed for an in vivo measurement of colonic motility at multiple time points.
Expulsion times shorter than 30 seconds and longer than 40 minutes were excluded.
Expulsion times were either averaged and compared between groups using an unpaired
students t-test, or normalized to the day 0 expulsion time, averaged and compared
between groups over time using a two-way ANOVA.

Fecal Output and Water Content
Fecal output is the measurement of number of fecal pellets produced during one
hour. To measure fecal water content, all pellets were collected during the fecal output
assay and immediately placed into closed Eppendorf tubes. At the end of one hour, the
total wet weight of all pellets was recorded. Pellets were then dried overnight at 50
degrees Celsius, and the dry weight was obtained the following day. The longer it takes a
pellet to pass through the colon, the dryer the pellet will be (i.e. more time for water
absorption leads to lower water content in the feces). Additionally, inflammation of the
colon affects the absorption and secretion action of the epithelium, and thus inflammation
of the colon also leads to increased water content. Fecal output and fecal water content
were assessed over the course of the experimental paradigm, and results were comparted
between vehicle and treatment groups.
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Data Analysis
Data are shown as mean +/- SEM for n number of animals. All data analysis was
completed using GraphPad Prism software (version 7.0; GraphPad Software, La Jolla,
CA). Data sets were examined before analysis to ensure that test assumptions were met
(variability and n values per group). Significance was determined using unpaired students
t-test, one-way ANOVA, or two-way ANOVA, with corrections for multiple comparison,
where appropriate. Statistical significance was defined as P values of less than 0.05.

IV. Results
Effect of Treatment on Disease Activity
Disease activity index (DAI) is an in vivo assay of disease severity that can be
taken at multiple time points throughout the course of colitis development and recovery.
It is common practice in the field to utilize such a rubric to understand disease
progression and recovery (Spohn et al., 2016, Wirtz et al., 2017). We tested whether
intracolonic treatment of 832Z (10 mg/kg) would improve recovery from colitis,
decreasing the DAI relative to the DAI of vehicle treated animals. This effect has
previously been seen with intracolonic administration of tegaserod, was blocked by
antagonist pre-treatment, and was not seen in 5-HT4 knockout mice (Spohn et al., 2016).
In the current study, DAI was assessed approximately every other day over the
15-day paradigm (3% DSS for 5 days, 10 days treatment). There was no significant effect
of either treatment (Figure 1A and 1B). Many other iterations of this paradigm were
performed with different drug delivery methods, different concentrations of drug, and
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different concentrations of DSS, and similar results were obtained (Supplemental Figures
1-4).

Effect of treatment on Histological Damage
Clinically diagnosis of colitis typically involves histological evaluation of patient
biopsies to determine the extent of inflammation. In experimental colitis, histological
evaluation of mucosal architecture and neutrophil infiltration is a common method used
to determine the extent of disease (Wirtz et al., 2017). Other methods, such as endoscopy,
allow for longitudinal evaluation of mucosal health; however, evaluation of histological
damage is the most robust readout. Given previous reports from our lab of improved
histological damage with the 5-HT4 receptor agonist tegaserod, we tested whether
histological damage would be alleviated by the 5-HT4 agonist 832Z.
We found no significant difference in histological damage scores between groups
(Figure 1C). Many other iterations of this paradigm were performed with different drug
delivery methods, different concentrations of drug, and different concentrations of DSS,
and comparable results were obtained (Supplemental Figures 1-4).

Effect of treatment on Epithelial Proliferation
Human and experimental colitis is associated with degradation of the epithelial
barrier. It has previously been shown that treatment with a 5-HT4 agonist promotes
epithelial proliferation in vitro and in vivo, resulting in improved barrier function and
improved histological appearance (Spohn et al., 2016). Thus, we expected that
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intracolonic treatment with the luminally restricted 5-HT4 agonist would result in an
increase of recently divided epithelial cells.
Our results indicate that there is no effect of treatment with 832Z on epithelial
proliferation (Figure 1D). Many other iterations of this paradigm were performed with
different drug delivery methods, different concentrations of drug, and different
concentrations of DSS, and similar results were obtained (Supplemental Figures 1-4).

Effect of treatment on fecal lipocalin-2 levels
Recently, lipocalin-2 (Lcn-2), also known as neutrophil gelatinase-associated
lipocalin in humans, has been identified as a non-invasive and sensitive biomarker of
intestinal inflammation in TNBS, DSS, and IL-10 knockout experimental colitis
(Chassaing et al., 2012, Hsieh et al., 2016). Fecal lipocalin levels are correlated with
disease severity and pro-inflammatory cytokine levels in DSS-induced colitis and
spontaneous colitis in IL-10 deficient mice (Chassaing et al., 2012). We tested whether
Lcn-2 levels increased with induction of colitis, and then decreased as mice recovered
from colitis. Additionally, we tested whether Lcn-2 levels for animals treated with 832Z
and tegaserod returned to baseline faster than vehicle treated animals. To our knowledge,
this is the first time lipocalin levels have been tested in CD-1 mice in response to
induction of DSS colitis, and more importantly, used to assess the efficacy of therapeutic
administration.
We found there was an increase of Lcn-2 levels in response to 3% DSS
administration, but no return to baseline during the recovery phase of the paradigm
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(Figure 1E; significant effect of day, p=0.038 by two-way ANOVA). With induction at
3% DSS, Lcn-2 levels increased to ~10,000 ng/g feces by day 10 post-induction, and
remained high through day 15. There were no significant differences between vehicle and
agonist treated groups (Figure 1E). A preliminary study was conducted using 2.5% and
3% DSS, and assessing Lcn-2 levels in untreated mice out to day 25. By day 10, levels
rose to ~ 7000 ng/g25, and only dropped to ~1000 ng/g by day 25 (Supplemental Figure
5; not significant). Many other iterations of this paradigm were performed with different
drug delivery methods, different concentrations of drug, and different concentrations of
DSS, and similar results were obtained (Supplemental Figures 1-4).

Effect of treatment on colonic motility
It has been established that clinical IBD and experimental colitis models are
associated with abdominal pain and changes in colonic motility and stool frequency
(Linden et al., 2004, Hoffman et al., 2011, Vivinus-Nebot et al., 2014, Spohn et al.,
2016). In animal models, it has been shown that colonic motility is decreased in colitis
and is associated with inflammation induced neuroplasticity (Hoffman et al., 2011,
Roberts et al., 2013). Additionally, it has been shown that treatment with a 5-HT4 agonist
rescues this slowing of colonic motility in mice and guinea pigs (Spohn et al., 2016).
Thus, we tested whether treatment with 832Z affected colitis induced dysmotility.
We found no changes in latency of bead expulsion between vehicle and treatment
groups when colitis was induced with 3% DSS (Figure 1F). Interestingly, we also did not
see the expected slowing of motility from days zero to five in response to colitis
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induction. This slowing of motility was noted in one experiment in response to 4% DSS,
with a significant effect of treatment (Supplemental Figure 1E; significant effect of
treatment, p=0.0098, by two-way ANOVA). Many other iterations of this paradigm were
performed with different drug delivery methods, different concentrations of drug, and
different concentrations of DSS, and similar results to that of 3% colitis induction were
obtained (Supplemental Figures 1-4).
Fecal output and fecal water content were only assessed in the first iteration of
this study (Supplemental Figures 1F and 1G). This experiment, along with others in our
lab, revealed that CD-1 mice have relatively high fecal water content at baseline (~60%)
as compared to C57BL6/J (data not shown). Given this finding, in addition to the fact that
diarrhea is a primary read out of colitis, we decided to discontinue this assay in the colitis
models. Additionally, bead expulsion appeared to be a more robust measure of colonic
motility than fecal output. Therefore, this assay was discontinued as well.

V. Discussion
This study tested the hypothesis that luminally restricted 5-HT4 agonists would
induce protective epithelial actions in DSS-induced experimental colitis. The results of
this study failed to support the hypothesis. With the conditions that were tested, the
luminally restricted 5-HT4 agonist did not exert protective effects detectable by our
outcome measures. Given previous research, these results are surprising and lead us to
believe that this study may not have involved conditions optimal for activity of the
luminally restricted agonist 832Z.
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Based on the results reported here, it appears that 832Z does not exert the same
protective actions that have previously been published for the 5-HT4 agonist tegaserod
(Spohn et al., 2016) Theoretically, this compound should stimulate the 5-HT4 receptor
and initiate the same protective actions – including stimulating epithelial proliferation,
mucus secretion and propulsive motility. Additionally, pharmacokinetic analysis of 832Z
performed by Takeda, indicate that this compound is present in colon tissue and the
colonic lumen up to 8 hours after gavage administration. While this does not indicate that
the drug is active once it reaches the colon, it does imply that there is compound binding
to receptors in the wall of the lumen. In our studies, delivery of the compound via enema
ensured that the compound was reaching mucosal receptors without being altered by
transit through the stomach and the small intestine. However, even with enema
administration, no effects of receptor stimulation were seen. This lack of an effect could
be explained by incorrect dosing of the compound or incompatible vehicle formulation.
Further studies will be required to test these possibilities.
An alternative explanation is that the mechanism of protective actions of
tegaserod are not due to activation of mucosal 5-HT4 receptors. If this were the case, a
luminally restricted 5-HT4 agonist would be ineffective. It is unknown if epithelial 5-HT4
receptors are located on the apical or basal side of intestinal epithelial cells. If the
receptor is located on the basal side of epithelial cells, an agonist would have to be
present in the lamina propria to stimulate receptor actions. This would require a
mechanism to transport a luminally delivered compound from the lumen into the lamia
propria. Under normal conditions, transport mechanisms are predominately expressed in
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the small intestine, not colonic epithelial cells. However, the transporter protein hPept1 is
aberrantly expressed in colonic epithelial cells of UC and CD patients, and have a role in
transporting bacterial di- and tri-peptides across the epithelial barrier (Merlin et al.,
2001). Another possible explanation is that tegaserod can diffuse across the compromised
epithelial barrier known to occur in experimental colitis, and the luminally restricted 5HT4 agonist cannot.
These explanations, while plausible, are unlikely. Previous results from our lab
demonstrate that intracolonic administration of tegaserod was significantly more effective
than systemic administration (IP) in reducing experimental colitis activity. Additionally,
the effect of intracolonic tegaserod was blocked by intraluminal administration of a 5HT4 selective antagonist. These results indicate that luminal 5-HT4 receptor activation is
necessary to induce the protective actions, and that it is a 5-HT4 receptor specific effect.
Future investigations involving conditional knockdown of the 5-HT4 receptor in epithelial
cells might be necessary to confirm the involvement of epithelial receptors in the
protective actions.
Tegaserod is also a 5-HT2B receptor antagonist. 5-HT2B receptors are located on
longitudinal and circular gastrointestinal smooth muscle cells and neurons within the
myenteric plexus (Engel et al., 1984, Borman et al., 2002). Additionally, tegaserod has
similar affinity for the 5-HT2B receptor as for the 5-HT4 receptor (Beattie et al., 2004).
Therefore, it is possible that any effects of tegaserod on motility could have been
complicated by 5-HT2B antagonism, but it is improbable that 5-HT2B receptor antagonism
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would interfere with protective epithelial actions. Furthermore, it is unknown the affinity
of the luminally restricted 5-HT4 agonist for the 5-HT2B receptor.
It is important to note that there were inconsistencies in the model of experimental
colitis that was used. We had significant variability in the extent of colitis that was
induced, and we were not able to reproduce the protective actions of tegaserod (Figure 1;
Supplemental Figures 3 and 4). A possible explanation for the variability in the colitis
model is due to the type of DSS used. Previous studies in our lab induced colitis with
DSS from MP Biomedicals (Solon, OH; molecular weight: 36,000-50,000), while the
current study used DSS from Affymetrix (Cleveland, OH; molecular weight: 40,00050,000). It is known that dosing and the molecular weight of DSS affect the quality and
severity of inflammation (Kitajima et al., 2000). Initial experiments in this study induced
colitis with 4% DSS, which resulted in many mice developing severe colitis (histological
damage scores >8 at day 5). For later studies, we induced colitis with 3% DSS to
stimulate development of a more moderate colitis (histological damage scores 4-8 at day
5). However, even with this reduction in colitis severity, we failed to see a recovery effect
of 832Z or tegaserod.
It was surprising that we were unable to recapitulate the effects of tegaserod. This
may be attributed to the inconsistencies in the model; therefore, these findings do not
overturn the previously reported data by our lab (Spohn et al., 2016).
Lastly, it is plausible that this particular luminally restricted compound, 832Z,
does not promote epithelial wound healing. Given that this is the first time 832Z has been
tested in vivo, it is possible that we are not seeing effects because this drug does not exert
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an effect on the mechanisms addressed in this study. Other research in our lab does
demonstrate a prokinetic effect of 832Z administration in naïve animals, and this effect is
blocked by a 5-HT4 antagonist (data not shown). These results are in line with our
hypothesis and indicate that the compound is active, and stimulates mucosal 5-HT4
receptors when administered by gavage or enema.
While this study revealed no effects of the luminally restricted 5-HT4 agonist
SYR313832Z, there is need for further study to confirm these findings. This study was
complicated by inconsistencies in the animal model and a lack of effect of the positive
control, tegaserod. While it is possible that this compound does not exert protective
actions in colitis, there is not sufficient evidence to make a definitive conclusion.

Concluding Remarks
This study tested the effects of a novel therapeutic agent, a luminally restricted 5HT4 agonist, in an in vivo animal model of colitis. The results show that this novel
compound does not exert protective epithelial actions or prokinetic effects in dextran
sodium sulfate induced colitis. However, further studies need to be done to assess this
novel compound with additional assays to make a definitive conclusion.
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Figure 1. Results from a 15-day recovery paradigm. Male CD1 mice, 8-10 weeks old.
Vehicle n=5*. 832Z n=8. Tegaserod n=7. Colitis induced with 3% DSS. Enema treatment
with vehicle (1% DMSO/0.9% saline), SYR313832Z (10 mg/kg SYR313832Z, 1%
DMSO/0.9% saline) or tegaserod (1 mg/kg tegaserod, 1% DMSO/0.9% saline). A)
Disease activity index over the course of the paradigm. There were no significant
differences in disease activity index (p=0.1598), however there was a significant effect of
day (p<0.0001) via 2-way ANOVA. B) Disease activity index for day 15. C) Histological
damage scores (p=0.7545 by one-way ANOVA). D) Percent Epithelial cells Ki67+,
reported as a ratio of Ki67+ cells:DAPI stained nuclei. Each data point represents one
animal, as an average of 3 crypts. (p=0.06217 by one-way ANOVA). E) Fecal Lipocalin2 levels for days 0, 5, 10 and 15. There is no significant effect of treatment (p=0.7123),
but there is a significant effect of day (p=0.038) by two-way ANOVA. F) Bead expulsion
times for Days 0, 5, and 15, reported as percent of day 0 expulsion time. All times are
calculated as the latency from wake to expulsion, and the normalized to the day 0
expulsion time. There was no significant effect of treatment (p=0.4298) or day
(p=0.7280) by two-way ANOVA. *One mouse was euthanized on day 9 due to >30%
weight loss and lethargy as per protocol.
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Significant effect of Day by two-way ANOVA. p<0.0001
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Figure Legend
Supplemental Figure 1. Results from a 15-day recovery paradigm. Male CD1 mice, 8-10
weeks old, 5 mice per group. Colitis induced with 4% DSS. Gavage treatment with
vehicle (0.5% methylcellulose, 50 mM citrate monohydrate in double distilled water, pH
3.0) or agonist (10 mg/kg SYR3138637, 0.5% methylcellulose, 50 mM citrate
monohydrate in double distilled water, pH 3.0). A) Disease activity index over the course
of the paradigm showed no significant effect of treatment (p=0.5103), but there was a
significant effect of day (p<0.0001) by two-way ANOVA. Mice reached a peak average
score of ~7, indicating moderate to severe colitis. B) Histological damage scores showed
no significant differences between groups (p=0.7245 by unpaired t-test). C) Bead
expulsion times for Days 0, 5, and 14, reported as percent of day 0 expulsion time. All
times are calculated as the latency from wake to expulsion, and the normalized to the day
0 expulsion time. Significant effect of treatment by two-way ANOVA (p=.0098). D)
Percent Epithelial cells Ki67+, reported as a ratio of Ki67+ cells:DAPI stained nuclei.
Each data point represents one animal, as an average of 3 crypts. There were no
significant differences between groups (p=0.5644 by unpaired t-test). E) Lcn-2 levels as
detected by ELISA showed no significant differences between groups (p=0.5264), but
there as a significant effect of day (p=0.0052) by two-way ANOVA. F) Fecal output
showed no effect of treatment (p=0.6006), but there was a significant effect of day
(p=0.0356) by two-way ANOVA. G) Fecal water content demonstrated to effect of
treatment (p=0.6418), but there was a significant effect of day (p<0.0001) by two-way
ANOVA.
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Supplemental Figure 2. Results from a 15-day recovery paradigm. Male CD1 mice, 8-10
weeks old, 5 mice per group. Colitis induced with 4% DSS. Gavage treatment with
vehicle (1% Tween80/Tap water) or agonist (10 mg/kg SYR313832Z, 1%Tween80/Tap
water). A) Disease activity index over the 15-day paradigm demonstrated no effect of
treatment (p=0.2123), but a significant effect of day (p<0.0001) by two-way ANOVA. B)
Histological damage scores demonstrated no significant differences between treatment
(p=0.4011) by an unpaired t-test. C) Percent Epithelial cells Ki67+, reported as a ratio of
Ki67+ cells:DAPI stained nuclei. Each data point represents one animal, as an average of
3 crypts. There was no significant difference between groups (p=0.1557) by an unpaired
t-test.
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Supplemental Figure 3. Results from a 15-day recovery paradigm. Male CD1 mice, 8-10
weeks old, 5 mice per group. Colitis induced with 4% DSS. Gavage treatment with
vehicle (1% Tween80/Tap water), agonist (10 mg/kg SYR313832Z, 1% Tween80/Tap
water) or enema treatment with tegaserod (1 mg/kg tegaserod, 1% DMSO/0.9% saline).
A) Disease activity index scores over the course of the paradigm. Tegaserod improved
DAI quicker than oral 832Z or vehicle, as seen by significant difference on days 8 and 10
(*p<0.05 between Tegaserod and both vehicle and oral 832Z; ψ p<0.05 between
Tegaserod and oral 832Z; analysis by two-way ANOVA with multiple comparisons,
Bonferroni corrections). B) Histological damage scores demonstrated no significant
differences between treatments at day 15 (p=0.7214) by one-way ANOVA. C) Fecal
Lipocalin-2 levels on days 0, 5, 7 and 15 as detected by ELISA demonstrated no effect of
treatment (p=0.3208), but a significant effect of day (p=0.0009) by two-way ANOVA. D)
Raw bead expulsion times, shown as latency from wake to expulsion in seconds
demonstrate no significant effect of treatment (p=0.4642) or day (p=0.9734) by two-way
ANOVA.
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Supplemental Figure 4. Results from a 15-day recovery paradigm. Male CD1 mice, 8-10
weeks old, 5 mice per group. Colitis induced with 4% DSS. Enema treatment with
vehicle (1% DMSO/0.9% saline), SYR313832Z (10 mg/kg or 1 mg/kg SYR313832Z, 1%
DMSO/0.9% saline) or tegaserod (1 mg/kg tegaserod, 1% DMSO/0.9% saline). A)
Disease activity index scores over the course of the paradigm demonstrated no effect of
treatment (p=0.6824), but a significant effect of day (p<0.0001) by two-way ANOVA. B)
Histological damage scores demonstrate no effect of treatment (p=0.9594) on day 15 by
one-way ANOVA. C) Percent Epithelial cells Ki67+, reported as a ratio of Ki67+
cells:DAPI stained nuclei. Each data point represents one animal, as an average of 3
crypts. There was no significant difference between groups (p=0.1017) by one-way
ANOVA. D) Bead expulsion times for Days 0, 5, and 15, reported as percent of day 0
expulsion time. All times are calculated as the latency from wake to expulsion, and the
normalized to the day 0 expulsion time. There was no significant effect of treatment
(p=0.1692) or day (p=0.1116) by two-way ANOVA.
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Figure Legend
Supplemental Figure 5. Results from a preliminary experiment inducing colitis with
either 3% or 2.5% DSS and collected fecal samples for Lcn-2 ELISA at days 5, 10, 15,
20 and 25. CD1 male mice, aged 8 weeks, 3 mice per group. There was no significant
effect of treatment (=0.4487) or day (p=0.2090) by two-way ANOVA.
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CHAPTER III: FINAL CONLUSIONS AND FUTURE DIRECTIONS
I. Summary and Conclusions
There is a drastic need for novel therapeutic agents for IBD. The current
therapies, including anti-inflammatory agents, immunosuppressants, and monoclonal
antibodies, do not serve all patient needs. A unique target for treatment in IBD is the
epithelial barrier. Compromised barrier function, or “leaky gut”, is a common feature of
IBD and may even contribute to the pathogenesis. This study aimed to explore mucosal
5-HT4 receptor activation using a luminally restricted 5-HT4 agonist as a novel
therapeutic target for IBD and other functional bowel disorders.
Results from my study reveal that the luminally restricted 5-HT4 agonist failed to
exert protective effects in DSS induced colitis. These results were surprising and prompt
the use of other paradigms and techniques to fully reveal the effects of this compound.

II. Future Directions
A primary concern of this study was the inconsistencies and variability within the
colitis model. It is known that induction of DSS colitis is dependent on both the mouse
strain and the molecular weight of DSS used (Kitajima et al., 2000, Chassaing et al.,
2014). I think it would be beneficial for future studies to utilize a different mouse strain
or DSS from a different company to explore the protective actions of 832Z. C57BL/6
mice are another commonly used strain to study DSS colitis, and I think attempting a
recovery paradigm with this strain would be beneficial. Additionally, other labs have
shown recovery of fecal lipocalin-2 levels in C57BL/6 mice. Given the lack of return to
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baseline of fecal lipocalin-2 levels in the CD-1 mice used in this study, it would be
beneficial to utilize a strain where we know that this biomarker can indicate a reduction
in inflammation. Furthermore, our lab has demonstrated prokinetic effects of 832Z in
naïve C57BL/6 mice, but not CD-1 mice. We initially used CD-1 mice for the colitis
studies based on the previous work in our lab showing protective epithelial actions of
tegaserod in CD-1 mice (Spohn et al., 2016). However, the CD-1 mice used in this study
had hemoccult positive stool at baseline, and sometimes soft stool, indicating a slight
dysregulation of epithelial barrier homeostasis prior to induction of colitis. We were
unable to identify the cause of these symptoms. C57BL/6 mice concurrently used in our
lab did not show the same symptoms. Therefore, I think it would be beneficial to test this
same hypothesis using C57BL/6 mice given that they are healthy at baseline and we have
seen effects of the compound on gastrointestinal motility. Additionally, I propose using a
more sensitive disease activity index rubric for the daily disease scoring. A protocol
update for chemically induced models of colitis included a disease activity index rubric
with more detailed scoring of stool consistency and fecal blood (see table 3) (Wirtz et al.,
2017). Utilization of this more detailed DAI rubric would take away some of the inherent
subjectivity of scoring stool consistency.
Score
0
1
2
3
4

Weight Loss
None
1-5%
5-10%
10-20%
>20%

Stool Consistency Occult/gross bleeding
Normal
Negative hemoccult
Soft but still formed
Soft
Positive hemoccult
Very soft; wet
Blood traces in stool
Watery diarrhea
Gross rectal bleeding

	
  

Table 3. Scoring system for disease activity index from Wirtz et al. (2017)
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Given the null results of this study in an in vivo model, I also suggest testing the
actions of 832Z with in vitro and ex vivo assays that specifically test the effects on barrier
function and wound healing. It is known that barrier function is disrupted in colitis and
experimental models of colitis (Stein et al., 1998, Turner, 2009). One of the three primary
actions of 5-HT4 agonists identified by our lab is improvement of barrier function,
facilitated by improved wound healing in colitis. Wound healing can be tested in vitro
using a scratch assay in Caco-2 cells, which specifically measures epithelial migration.
Caco-2 cells are a human epithelial adenocarcinoma cell line that are frequently used to
assess properties of intestinal epithelial cells in vitro. Previous reports in our lab
demonstrate that tegaserod improves closure of the scratch over vehicle control, and that
this is blocked by co-administration of a 5-HT4 selective antagonist (Spohn et al., 2016).
Another important component of wound healing is the rate of apoptosis. Reactive oxygen
species caused by oxidative stress are present in colitis and contribute to epithelial
apoptosis (Shi et al., 2011, Novak and Mollen, 2015, Spohn et al., 2016). To assess the
effect of 832Z on reactive oxygen species induced apoptosis, Caco-2 cells are pretreated
with the compound, exposed to H2O2, and then the percent of cells undergoing apoptosis
is measured. This question could also be answered in vivo by using a colitis prevention
paradigm and performing a TUNEL assay on sections of colon after treatment. Barrier
function or intestinal permeability can be specifically tested ex vivo or in vitro using
Ussing chamber assays or measuring transepithelial resistance of cultured cells,
respectively.
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This study used one method to assess colonic motility in inflamed mice. There are
many other assays, some more sensitive than bead expulsion, that can be utilized. Current
data from our lab indicate prokinetic effects with acute treatment of 832Z in naïve mice
using measures of whole gastrointestinal transit. Additionally, smaller motor events such
as colonic migrating motor complexes and slow wave motor events can be videocaptured from ex vivo colon preparations and analyzed to show changes in these more
minute phenomena. These ex vivo assays can be performed after administration of
compound to the animal, or with application in the ex vivo bath preparation. Lastly, the
integrity of the neuromuscular junction can be assessed using intracellular
electrophysiology to record junction potentials from longitudinal smooth muscle cells.
In conclusion, there are many other detection measures that can be utilitzed to
assess the effects of the luminally restricted 5-HT4 agonist 832Z. While my study did not
demonstrate any effects of this compound, it was the first study to explore the novel
therapeutic mechanism of luminally restricted compounds in a model of experimental
colitis. Additionally, this was the first study to my knowledge assessing fecal lipocalin-2
levels in CD-1 mice in response to a therapeutic treatment in a model of colitis. These
results will inform future studies into the protective epithelial actions of this and future
luminally restricted 5-HT4 agonists.
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